|
Session 85
Poster Abstracts
Vaccines: Neutralizing Antibodies and Clinical Trials
Wednesday, 1 - 4 pm
Poster Hall |
| 469 |
Exceptional Potency and Breadth of HIV-1 Neutralization by a Human scFv Antibody
M Y Zhang1, A Rosa Borges2, V Choudhry1, H Lu3, Anthony Dimitrov*4, T Fouts4, S Jiang3, V Polonis2, D Montefiori5, and D Dimitrov1
1NCI-Frederick, NIH, MD, US; 2US Military HIV Res Prgm, Rockville, MD, US; 3Lindsley F Kimball Res Inst, New York Blood Ctr, New York, NY, US; 4Profectus BioSci, Inc, Baltimore, MD, US; and 5Duke Univ Med Ctr, Durham, NC, US |
| 470 |
Generating Transgenic Mice Expressing HIV-1 Receptors on B-cell Surface for Eliciting Antibodies against Envelope Fusion Intermediates
Adam Penn-Nicholson*, M Lederman, and M Cho
Case Western Reserve Univ, Cleveland, OH, US |
| 471 |
Construction and Characterization of Antigenic Properties of gp120 Outer Domain
Soon-Jeung Kim*, D Han, A Penn-Nicholson, Y Qin, and M Cho
Case Western Reserve Univ, Cleveland, OH, US |
| 472 |
Characterization of Antigenic and Immunogenic Properties of gp41 Membrane Proximal Region
Dong Han*, A Penn-Nicholson, S J Kim, H Park, R Ansari, and M Cho
Case Western Reserve Univ, Cleveland, OH, US |
473
 |
Investigation of HIV-1 Inactivation by Non-neutralizing Antibodies
S Campbell1, R Center1, A Schöenberner1, A Wheatley1, J Howard1, A Kelleher2, B Loveland3, and Damian Purcell*1
1Univ of Melbourne, Parkville, Australia; 2Natl Ctr for HIV Epidemiology and Clin Res, Darlinghurst, Australia; and 3Austin Res Inst, Heidelberg, Australia |
474
|
A Phase I Study to Evaluate the Safety and Immunogenicity of a Recombinant Adeno-associated Virus Vaccine
Jan van Lunzen*1, S Mehendale2, N Clumeck3, E Vets4, J Rockstroh5, P Johnson6, C Schmidt7, J Excler8, S Kochhar8, and A Heald9
1Univ Med Ctr Hamburg-Eppendorf, Germany; 2Natl AIDS Res Inst, Pune, India; 3St Pierre Univ Hosp, Brussels, Belgium; 4SGS Biopharma, Antwerp, Belgium; 5Univ Clin, Bonn, Germany; 6Children's Hosp of Philadelphia, PA, US; 7Intl AIDS Vaccine Initiative, New York, NY, US; 8Intl AIDS Vaccine Initiative, New Delhi, India; and 9Targeted Genetics Corp, Seattle, WA, US |
475
|
Dose-sparing Intracutaneous Influenza Vaccination in HIV-infected Patients Is Immunogenic and Well Tolerated
Luc Gelinck*1, L Visser1, G Rimmelzwaan2, and F Kroon1
1Leiden Univ Med Ctr, The Netherlands and 2Erasmus Med Ctr, Rotterdam, The Netherlands |
| 476 |
Recruitment of HIV-uninfected Volunteers, Measurement of HIV Incidence, and Characterization of Early Infection at Multiple Sites in Africa in Anticipation of Preventive HIV Vaccine Efficacy Trials
A Kamali1, E Karita2, Kayitesi Kayitenkore*2, C Vwalika2, S Lakhi2, O Anzala3, E Sanders4,5, E Sanders4,5, A Kebba1, L Bekker6, J Gilmour7, and the IAVI Vaccine Efficacy Trial Collaborative Network
1Med Res Council/Uganda Virus Res Inst, Masaka and Entebbe; 2Rwanda Zambia HIV Res Group, Kigali and Lusaka; 3Kenya AIDS Vaccine Initiative, Nairobi; 4Kenya Med Res Inst, Kilifi; 5Oxford Univ, UK; 6Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa; and 7Intl AIDS Vaccine Initiative, New York, NY, US; Nairobi, Kenya; Johannesburg, South Africa; Amsterdam, The Netherlands; New Delhi, India |
|
